Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Letolizumab (Primary)
- Indications Immune thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Nov 2016 Planned End Date changed from 1 May 2017 to 1 Feb 2018.